Ann: iPPS shows 3-year equivalent durability in OA Canine Study, page-32

I remember it specifically, as I loaded up on PAR and sold out early August, suspecting a capital raise soon on the agenda (all documented on HC - I wished PAR shareholders well on exit, explaining why). So, have to disagree as clearly shown in the chart above (go look at the data). PAR moved off a $0.855 low on 29 June EOFY tax selling, back above $1 in early July.

It announced the NFL Alumini partnership on 13 July, did an investor webinar on 15 July, gave a heap of positive information in an Appendix 4C end of July and then an MPS recruitment/indication update in MPS on 8 August. The stock went from $1.05 to $2.15 across three weeks of positive information/updates infused pricing momentum.

I got lucky on timing, if not notion, the company announcing its capital raise on 11 August and the stock close at $1.42 the first day's trading thereafter.

Again, past prices not necessarily reflective of future prices, but I am banking on another EOFY selling bounce and good news spike in the new fin. year (MPS 1 & VI primary endpoint read-outs 2H23?) and bought more today. I will trim my position on any profitable spikes and absolutely will sell out somewhere above $2 if it hits that mark again in 2023 (doubt it). Small cap Bio-tech's so often spike too high on good news and fall far too low between, particularly when the CEO's casually reveal trial delays in 'fireside chats' or executive teams poorly report trial results.

Paradigm's treatment great in theory/potential, but as usual in Aussie bio-techs, this executive team's execution/transition to commercialisation is tardy at best.